Clinical Trial Update: Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

View source ↗

Summary

Real-world analysis comparing persistence and adherence to Ofatumumab versus self-injectable and oral disease-modifying therapies in multiple sclerosis patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Status: COMPLETED